PLoS One:中国人群出血性卒中和缺血性卒中的时间趋势(2001-2012)

2016-10-30 MedSci MedSci原创

背景:脑卒中的临床流行病学已在高加索人群中得到了广泛的研究,但随着时间的改变,缺血/出血性卒中的比例,变化是不太清楚,尤其是中国人群。目的:研究者的目的是在大型中国人口队列中,研究与年龄相关的缺血性和出血性卒中的决定因素及时间趋势。方法:使用2001到2012间中国西南部医疗保险数据库,年龄校正的缺血性和出血性卒中发病率的变化趋势,及与年龄相关的危险因素。结果: 无卒中史的425901(52.4%

背景:脑卒中的临床流行病学已在高加索人群中得到了广泛的研究,但随着时间的改变,缺血/出血性卒中的比例,变化是不太清楚,尤其是中国人群。

目的:研究者的目的是在大型中国人口队列中,研究与年龄相关的缺血性和出血性卒中的决定因素及时间趋势。

方法:使用2001到2012间中国西南部医疗保险数据库,年龄校正的缺血性和出血性卒中发病率的变化趋势,及与年龄相关的危险因素。

结果:无卒中史的425901(52.4%为男性,平均年龄54岁)受试者中,2002-2007年缺血性卒中率(每1000患者-年)下降,2008-2012年之间,保持大致相同。出血性卒中率显示出类似的趋势,2008-2012年之间,约1.3~1.9。与年龄<6 5的患者相比,缺血性和出血性卒中的发生率明显高于老年人口(年龄<65vs年龄≥65:缺血性:3.64,3.33-4.00,vs 14.33,14.01-14.60;出血:1.09、1.00-1.10 VS 2.52, 240-270)。老年人和超高龄老年人出血性卒中率之间没有显著差异。缺血性和出血性卒中有相同的危险因素(年龄、高血压、冠状动脉疾病(CAD)、血管疾病和糖尿病)。年龄小于75岁的受试者,CAD(7.17,4.14-12.37)和糖尿病(3.27,2.42-4.42)对出血性卒中贡献最大(P均<0.001)。在超高龄老人中,血管疾病(2.24,1.49-3.37),CAD和糖尿病是出血性卒中的风险因子。

结论:在中国的大型队列研究者,与出血性卒中相比,老龄化增加缺血性卒中风险。冠心病、血管性疾病、糖尿病和高血压是中国超高龄老人出血性卒中发生的主要原因。

原始出处:

Guo Y, Wang H, et al. Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. PLoS One. 2016 Sep 29


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
    2016-11-02 保守主义

    又学习了~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1789854, encodeId=07241e89854ef, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Mar 10 01:58:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806118, encodeId=3c6418061186a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Mar 05 12:58:00 CST 2017, time=2017-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951596, encodeId=70c8195159608, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Tue May 16 16:58:00 CST 2017, time=2017-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152825, encodeId=6ef315282579, content=又学习了~, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0f31631005, createdName=保守主义, createdTime=Wed Nov 02 07:33:21 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319559, encodeId=167f13195599c, content=<a href='/topic/show?id=1dc13145ef8' target=_blank style='color:#2F92EE;'>#出血性卒中#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31457, encryptionId=1dc13145ef8, topicName=出血性卒中)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Tue Nov 01 09:58:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892808, encodeId=f9cb189280896, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Oct 11 07:58:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]

相关资讯

CSCO 2016:邵志敏教授——中国乳腺癌防治如何突破困境?

2016年,厦门的CSCO大会上,来自复旦大学附属肿瘤医院的邵志敏教授为我们讲述了中国乳腺癌的现状和问题。(邵志敏教授)乳腺癌是女性癌症第一位即使是从世界范围来说,乳腺癌也是位居女性癌症发病之首,全球每年新发乳腺癌病例约167.1万,每年约52.2万患者死于乳腺癌,发达国家乳腺癌发病率相对于欠发达国家更高。(乳腺癌世界地图,上图为发病率地图,下图为死亡率地图。可以看出,发达国家由于早筛等措施到

Circulation:心血管病风险预测中国模型

如果能够知道10年后,每个人罹患急性心肌梗死、脑卒中等动脉粥样硬化性心血管疾病(ASCVD)的风险,就可以提前预警。日前,由中国医学科学院阜外医院副院长顾东风教授领衔的团队,顺利完成了中国ASCVD风险预测研究(简称China-PAR)。通过输入年龄、总胆固醇、高密度脂蛋白胆固醇、糖尿病等综合指标数据,便能够借助数学模型,计算出10年后个人ASCVD的发病风险。近日,这一研究成果论文在著名国际医学

Sci Rep:中国研究证实——睡眠习惯与卒中发生相关

在西方人群中,睡眠习惯与脑卒中相关,中国对这种关系的研究很少见。此外,卒中亚型之间的差异仍不清楚。本研究旨在探讨中国南部地区居民的总脑卒中,包括缺血性和出血性,与睡眠习惯的关系。研究者进行了一项病例对照研究,第一次卒中入院的患者及社区对照组。共有333例患者(缺血性脑卒中n = 223  ,占67%,;出血性卒中患者N = 110、占23%,)和547例对照组研究对象。受试者完成一份结构化问卷,以

“海南模式”看中国医药创新

9月22日,硕果累累的重磅抗癌新药Keytruda(中文名“派姆单抗”)在各级政府部门、医疗机构与海关人员的通力合作之下,通过一系列审批流程入驻海南省肿瘤医院成美国际医学中心。Keytruda的快速入驻,正式开启了国外抗癌新药进入中国的“海南模式”。 ▲Keytruda的快速入驻,开启了国外新药进入中国的“海南模式”(图片来源:默沙东) “海南模式”是中国医药政策的又一重要创新。2013年

ISRD & ATS 2016:白春学教授谈中国如何影响国际呼吸界

金秋十月,满载硕果。在这个收获的季节里,呼吸界人士欢聚上海,共同迎来了第十二届国际呼吸学会暨ATS呼吸论坛。16日下午,在呼吸基金申请经验交流专场,中国肺癌防治联盟主席、上海市呼吸病研究所所长、复旦大学附属中山医院呼吸科主任白春学教授作了一场精彩的演讲,演讲的主题为“中国如何影响国际呼吸界”。中国为何要影响国际业界白春学教授自豪的说道,2001年11月10日晚,第四届世贸组织(WTO)部长会议

Circulation:量身定做—中国人群动脉粥样硬化性心血管疾病十年风险预测模型问世

个体风险的准确评估对于动脉粥样硬化心血管疾病(ASCVD)的指导和预防有很大的价值。然而,常用的预测模型通常是在白种人群中建立的。该项目旨在在四个中国当代队列中,开发并验证ASCVD的十年风险预测模型。来自中国的研究人员开展了两项前瞻性研究,这两项研究作为衍生队列来开发10年ASCVD风险方程,共涉及21320名中国参与者。外部验证在两个独立的中国队列中进行评估,这两个队列分别有14123名参与者